RevoDx HBV/HCV/HIV-1/2 qPCR Kit

The HBV/HCV/HIV-1&2 NAT assay is important for several reasons: NAT assays can detect the genetic material of viruses (RNA or DNA) at an early stage of infection, often before antibodies are produced by the immune system. This early detection allows for prompt medical intervention and management of infected individuals, potentially preventing the progression of the disease and reducing the risk of transmission to others. Compared to traditional antibody-based tests, NAT assays significantly reduce the window period—the time between infection and detection—thereby minimizing the chances of false-negative results during this critical phase. NAT assays are crucial for screening blood donations in blood banks to ensure the safety of blood transfusions. By detecting the presence of viral genetic material, these assays help prevent the transmission of HBV, HCV, HIV-1, and HIV-2 through contaminated blood products. Similarly, NAT assays are used to screen organ donations for these viruses, reducing the risk of transmitting infections to transplant recipients. By accurately identifying individuals infected with HBV, HCV, HIV-1, and HIV-2, NAT assays play a vital role in public health surveillance efforts, enabling health authorities to monitor the prevalence of these infections, implement appropriate preventive measures, and allocate resources effectively. For individuals at risk of contracting these viruses, such as healthcare workers or individuals with high-risk behaviors, regular NAT testing can provide peace of mind and help in early diagnosis and management of infections. Overall, the HBV/HCV/HIV-1&2 NAT assay is essential for early diagnosis, prevention of transmission, and effective management of HBV, HCV, HIV-1, and HIV-2 infections, contributing significantly to public health and individual well-being.

Intended Use

RevoDx HBV/HCV/HIV1&2 qPCR Kit is a real-time PCR test intended for the qualitative detection of Hepatitis B virus (HBV) DNA, Hepatitis C virus (HCV) RNA and Human Immunodeficiency virus type 1 and type 2 (HIV-1 & HIV-2) RNA in human serum or plasma (EDTA).